Variation in the human genome and risk to common disease

Pharmacogenomics

Volumn 5, Issue 2, 2004, Pages 157-161

  de Bakker, Paul I W ^a   Saxena, Richa ^a   Graham, Robert R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALANINE; APOLIPOPROTEIN E; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR B; GLIBENCLAMIDE; GLIPIZIDE; HLA ANTIGEN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOTRANSFERASE; PROLINE; PROTEIN RET; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 1; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COGNITIVE DEFECT; COLON CANCER; COMPARATIVE GENE MAPPING; CONFERENCE PAPER; DRUG MECHANISM; FAT INTAKE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC DATABASE; GENETIC RECOMBINATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LINKAGE ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENETICS; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

DISEASE SUSCEPTIBILITY; GENE EXPRESSION PROFILING; GENOME, HUMAN; HAPLOTYPES; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1542604095     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.5.2.157.27480     Document Type: Conference Paper

References (12)

1. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33, 177-182 (2003).
2. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES: High-resolution haplotype structure in the human genome. Nat. Genet. 29, 229-232 (2001).
3. The International HapMap Consortium: The International HapMap Project. Nature 426, 789-796 (2003).
4. Jeffreys AJ, Kauppi L, Neumann R. Intensely punctuate meiotic recombination in the class II region of the major histocompatibility complex. Nat. Genet. 29, 217-222 (2001).
5. Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A. Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease. Nat. Genet. 32, 237-244 (2002).
6. + secretion. Nat. Genet. 35, 372-376 (2003).
7. Florez JC, Hirschhorn J, Altshuler D: The inherited basis of diabetes mellitus: Implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet. 4, 257-291 (2003).
8. Memisoglu A, Hu FB, Hankinson SE et al.: Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARγ gene and Type 2 diabetes. Diabetes Care 26, 2915-2917 (2003).
9. Goldstein DB, Tate SK, Sisodiya SM: Pharmacogenetics goes genomic. Nat. Rev. Genet. 4(12), 937-947 (2003).
10. Kellis M, Patterson N, Endrizzi M, Birren B, Lander ES: Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature 423, 241-254 (2003).
11. Yvert G, Brem RB, Whittle J et al.: Transacting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors. Nat. Genet. 35, 57-64 (2003).
12. Lindpaintner K: The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1, 463-469 (2002).